Immunogenicity and safety of an inactivated hepatitis a vaccine in children with down syndrome

Journal of Pediatric Gastroenterology and Nutrition

Volumn 39, Issue 4, 2004, Pages 337-340

  Ferreira, Cristina Targa ^a   Leite, Júlio César ^a   Taniguchi, Adriano ^a   Vieira, Sandra Maria ^a   Pereira Lima, Jorge ^a   Silveira, Themis Reverbel da ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Down syndrome; Hepatitis A; Hepatitis A vaccine; Immunocompromised children; Immunogenicity of hepatitis A vaccine

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE;

ARTICLE; BLOOD; CHILD; DOWN SYNDROME; HEPATITIS A; HUMAN; IMMUNOLOGY; INFANT; PRESCHOOL CHILD; PROSPECTIVE STUDY;

CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HUMANS; INFANT; PROSPECTIVE STUDIES;

EID: 28344449325     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/00005176-200410000-00007     Document Type: Article

References (29)

1. Lopéz EL, Xifró MC, Torrado LE, et al. Safety and immunogenicity of a pediatric formulation of inactivated hepatitis A vaccine in Argentinean children. Pediatr Infect Dis J 2001;20:48-52.
2. Tapia-Conyer R, Santos JI, Cavalcanti AM, et al. Hepatitis A in Latin America: a changing epidemiologic pattern. Am J Trop Med Hyg 1999;61:825-9.
3. Ciocca M, Ramonet M, Sasbón J, et al. Acute liver failure in children: prospective study. Hepatology 1998;28(Suppl):1369.
4. Ginsberg GM, Slater PE, Shouval D. Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity. J Hepatol 2001;34:92-9.
5. Cossarizza A, Monti D, Montagnani G, et al. Precocious aging of the immune system in Down’s syndrome: alterations of B lymphocytes, T-lymphocyte subsets, and cells with natural killer markers. Am J Med Genet 1990;7:213-18.
6. Noble RL, Warren RP. Altered T-cell subsets and defective T-cell function in young children with Down syndrome (trisomy 21). Immunol Invest 1987;16:371-82.
7. Avanzini MA, Monafo V, Amici M, et al. Humoral immunodeficiencies in Down’s syndrome: serum IgG subclass and antibody response to hepatitis B vaccine. Am J Med Genet 1990;7:231-3.
8. Ribeiro LMA, Jacob CMA, Pastorino AC, et al. Evaluation of factors associated with recurrent and/or severe infections in patients with Down’s syndrome. J Pediatr 2003;79:141-8.
9. UgazioAG, Jayakar SD, Marcioni AF, et al. Immunodeficiency in Down’s syndrome: relationship between presence of human thyroglobulin antibodies and HBsAg carrier status. Eur J Pediatr 1977;126:139-46.
10. Nespoli L, Burgio GR, Ugazio AG, Maccario R. Immunological features of Down’s syndrome: a review. J Intellect Disabil Res 1993;37:543-51.
11. Spina CA, Smith D, Korn E, et al. Altered cellular immune functions in patients with Down’s syndrome. Am J Dis Child 1981;135:251-5.
12. Ugazio AG, Maccario R, Notarangelo LD, Burgio GR. Immunology of Down syndrome: a review. Am J Med Genet 1990;7:204-12.
13. Gordon MC, Sinha SK, Carlson SD. Antibody responses to influenza vaccine in patients with Down syndrome. Am J Ment Defic 1971;75:391-9.
14. Avanzini MA. IgG subclass deficiency in patients with Down’s syndrome and aberrant hepatitis B vaccine response. Scand J Immunol 1988;28:465-70.
15. Troisi CL, Heiberg DA, Hollinger B. Normal immune response to hepatitis B vaccine in patients with Down’s syndrome: a basis for immunization guidelines. JAMA 1985;254:3196-9.
16. Cohen I, ed. Health care guidelines for individuals with Down syndrome: 1999 revision. May 13, 2002. Available at:. Accessed April 29, 2004.
17. American Academy of Pediatrics. Health supervision for children with Down syndrome. Pediatrics 2001;107:442-9.
18. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271:1328-34.
19. Keeffe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998;27:881-6.
20. Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992;327:453-7.
21. Centers for Disease Control. Prevention of hepatitis A through active and passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1999;48(RR-12):1-37.
22. American Academy of Pediatrics. Committee on Infectious Diseases. Prevention of hepatitis A infection: guidelines for use of hepatitis A vaccine and immune globulin. Pediatrics 1996;98:1207-15.
23. Sociedade Brasileira de Pediatria. Indicações de Vacinas 2001. Available at:. Accessed April 29, 2004.
24. Schwarz KB, Balistreri W. Viral hepatitis. In: American Liver Foundation. Pediatric Liver Research Agenda 2000: A Blueprint for the Future Research Goals and Strategies to Treat, Prevent, and Conquer Childhood Liver Diseases. New York: American Liver Foundation; 2000;56-63.
25. Cederna JB, Klizman D, Stapleton JT. Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine. Vaccine 2000;18:892-8.
26. Lockitch G, Singh VK, Puterman ML, et al. Age-related changes in humoral and cell-mediated immunity in Down syndrome children living at home. Pediatr Res 1987;22:536-40.
27. Burgio GR, Ugazio AG, Nespoli L, et al. Derangements of immunoglobulin levels, phytohemaglutinin responsiveness and T and B cell markers in Down’s syndrome at different age. Eur J Immunol 1975;5:600-3.
28. Garcia O, Bruguera M, Mayor A, et al. Hepatitis B at an open institution for the mentally retarded. Immunogenic effect of a recombinant anti-hepatitis-B vaccine. Enferm Infec Microbiol Clin 1990;8:148-52.
29. Renner F, Andrle M, Horak W, Rett A. Hepatitis A and B in non-institutionalized mentally retarded patients. Hepatogastroenterology 1985;32:175-7.